Tumor Targeting by Fusobacterium nucleatum: A Pilot Study and Future Perspectives

Area of Science:

• Oncology
• Microbiology
• Molecular Biology

Background:

• Colorectal adenocarcinoma (CRC) presents high mortality rates and is often colonized by *Fusobacterium nucleatum*.
• *Fusobacterium nucleatum* promotes tumor progression and immune evasion in CRC.
• Fusobacterial colonization is mediated by the Fap2 lectin binding to tumor-expressed Gal-GalNAc moieties.

Purpose of the Study:

• To investigate the presence of Gal-GalNAc moieties in various adenocarcinomas beyond CRC.
• To explore the potential of targeting *Fusobacterium nucleatum* for cancer therapy.

Main Methods:

• Analysis of Gal-Gal-NAc expression levels in multiple human adenocarcinoma tissues.
• Review of existing literature on fusobacterial presence in non-colorectal tumors.

Main Results:

• High levels of Gal-GalNAc were detected in adenocarcinomas of the stomach, prostate, ovary, colon, uterus, pancreas, breast, lung, and esophagus.
• These findings correlate with reports of fusobacterial DNA in some of these tumors.
• *Fusobacterium nucleatum*'s role in tumorigenesis and immune evasion is established.

Conclusions:

• The presence of Gal-GalNAc in various adenocarcinomas suggests a broader role for *Fusobacterium nucleatum* in cancer.
• Eliminating fusobacteria may improve treatment outcomes for these cancers.
• *Fusobacterium nucleatum* could be engineered as a therapeutic platform for treating multiple adenocarcinomas.